I. Poloxamer-formulated plasmid DNA-based human cytomegalovirus vaccine: evaluation of plasmid DNA biodistribution/persistence and integration.

Preclinical studies were conducted in mice and rabbits to evaluate biodistribution/persistence and potential integration of plasmid DNA (pDNA) after intramuscular administration of a poloxamer-formulated pDNAbased vaccine, VCL-CT01, encoding gB, pp65, and IE1 human cytomegalovirus (hCMV) immunogens. Tissue distribution in mice vaccinated with VCL-CT01 was compared with that in mice vaccinated with a phosphate- buffered saline (PBS)-formulated control pDNA vaccine. Residual pDNA copy number (PCN), in selected tissues collected on days 3, 30, and 60 after vaccination, was measured by quantitative polymerase chain reaction. In VCL-CT01-vaccinated mice and in control pDNA-vaccinated mice, pDNA was below the limit of detection by day 60 in all tissues except the injection site. Clearance of pDNA from the injection site was slower in VCL-CT01-vaccinated mice compared with PBS-pDNA-vaccinated mice. An integration study was conducted in rabbits to determine whether pDNA integration into the genome of the vaccinated animal contributed to pDNA persistence. Residual pDNA in VCL-CT01-injected rabbit muscle collected 60 days after vaccination (geometric mean of 1085 PCN/microg total DNA) was comparable to that observed in VCL-CT01- injected mouse muscle (geometric mean of 1471 PCN/microg total DNA) collected at the same time point. pDNA integration was not detectable by column agarose gel electrophoresis despite the persistence of pDNA at the injection site 60 days after vaccination. Therefore the risk of genomic integration of hCMV pDNA formulated with poloxamer was considered negligible.

[1]  D. Kaslow,et al.  II. Cationic lipid-formulated plasmid DNA-based Bacillus anthracis vaccine: evaluation of plasmid DNA persistence and integration potential. , 2005, Human gene therapy.

[2]  D. Kaslow,et al.  A DNA-Based Vaccine for the Prevention of Human Cytomegalovirus-Associated Diseases , 2005, Human vaccines.

[3]  R. K. Evans,et al.  Characterization and biological evaluation of a microparticle adjuvant formulation for plasmid DNA vaccines. , 2004, Journal of pharmaceutical sciences.

[4]  G. Ciliberto,et al.  Detection of integration of plasmid DNA into host genomic DNA following intramuscular injection and electroporation , 2004, Gene Therapy.

[5]  S. Plotkin.  Congenital cytomegalovirus infection and its prevention. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  J. Perrard,et al.  Biodistribution and safety studies of hDel‐1 plasmid‐based gene therapy in mouse and rabbit models , 2004, The Journal of pharmacy and pharmacology.

[7]  J. Torras,et al.  Intramuscular SP1017‐formulated DNA electrotransfer enhances transgene expression and distributes hHGF to different rat tissues , 2004, The journal of gene medicine.

[8]  W. Kim,et al.  Safety Evaluation of GX-12, a New HIV Therapeutic Vaccine: Investigation of Integration into the Host Genome and Expression in the Reproductive Organs , 2003, Intervirology.

[9]  A. Kabanov,et al.  Design and formulation of polyplexes based on pluronic-polyethyleneimine conjugates for gene transfer. , 2002, Bioconjugate chemistry.

[10]  L. Picker,et al.  Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. , 2002, The Journal of infectious diseases.

[11]  C. Wheeler,et al.  Electroporation-facilitated delivery of plasmid DNA in skeletal muscle: plasmid dependence of muscle damage and effect of poloxamer 188. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  L. Borysiewicz,et al.  Human Cytomegalovirus pp65- and Immediate Early 1 Antigen-Specific HLA Class I-Restricted Cytotoxic T Cell Responses Induced by Cross-Presentation of Viral Antigens1 , 2001, The Journal of Immunology.

[13]  J. Zaia,et al.  Site-directed mutation in a conserved kinase domain of human cytomegalovirus-pp65 with preservation of cytotoxic T lymphocyte targeting. , 2001, Vaccine.

[14]  W. W. Nichols,et al.  Plasmid DNA Vaccines: Tissue Distribution and Effects of DNA Sequence, Adjuvants and Delivery Method on Integration into Host DNA , 2001, Intervirology.

[15]  W. W. Nichols,et al.  Plasmid DNA Vaccines: Investigation of Integration into Host Cellular DNA following Intramuscular Injection in Mice , 2001, Intervirology.

[16]  S. Hoffman,et al.  Plasmid DNA malaria vaccine: tissue distribution and safety studies in mice and rabbits. , 1999, Human gene therapy.

[17]  S. Hoffman,et al.  Plasmid DNA malaria vaccine: the potential for genomic integration after intramuscular injection. , 1999, Human gene therapy.

[18]  K. Anwer,et al.  Biodistribution and gene expression of lipid/plasmid complexes after systemic administration. , 1998, Human gene therapy.

[19]  J. T. Macgregor,et al.  Determination of tissue distribution of an intramuscular plasmid vaccine using PCR and in situ DNA hybridization. , 1996, Human gene therapy.

[20]  Andrew N. Rowan.  Guide for the Care and Use of Laboratory Animals , 1996 .

[21]  W. W. Nichols,et al.  Potential DNA Vaccine Integration into Host Cell Genome , 1995, Annals of the New York Academy of Sciences.

[22]  G. Acsadi,et al.  Long-term persistence of plasmid DNA and foreign gene expression in mouse muscle. , 1992, Human molecular genetics.

[23]  W. Britt,et al.  The outcome of congenital cytomegalovirus infection in relation to maternal antibody status , 1992, The New England journal of medicine.

[24]  Tom Maniatis,et al.  Transformation of mammalian cells with genes from procaryotes and eucaryotes , 1979, Cell.

[25]  R. Proulx,et al.  A combination of poloxamers increases gene expression of plasmid DNA in skeletal muscle , 2000, Gene Therapy.

[26]  J. Cole,et al.  International Commission for Protection Against Environmental Mutagens and Carcinogens. Working paper no. 3. Somatic mutant frequency, mutation rates and mutational spectra in the human population in vivo. , 1994, Mutation research.

[27]  W. Busse.  Viral Infections of Humans , 1976, Springer US.